News Summary
NegativeMedline reported solid Q2 2026 revenue growth (+11.6% YoY) and raised organic sales guidance to 9-10%, but was severely impacted by multiple FDA recalls and warning letters tied to product sterility and device safety failures, triggering a ~13% stock drop and securities fraud investigation. Analyst price target cuts from five major firms (JPMorgan, Morgan Stanley, Baird, Barclays, UBS) reflect loss of investor confidence despite maintained operational performance.
Red flags
- •Major FDA recall involving 1,280+ lots of convenience kits with sterile applicator failures
- •FDA warning letter regarding angiographic syringes with design verification process deficiencies; devices unwind during use causing biohazard/infection/embolism risks
- •Securities fraud investigation initiated by law firm Bleichmar Fonti & Auld following product quality disclosures
- •Stock price dropped approximately 13% following recall announcements
- •Five analyst price target cuts in rapid succession (Aug 6 - Oct 9, 2026), with targets reduced 10-17% from prior levels
- •FDA expressed dissatisfaction with company's corrective response to device safety issues
Funds Reducing / Exiting (4)
| Fund | Manager | Shares Held | ∆ Shares | Position Value | % of Fund | QoQ | Status |
|---|---|---|---|---|---|---|---|
| Viking Global | Andreas Halvorsen | 4.8M | -6,592,741 | $191M | 1.4% | -58% | Existing |
| Durable Capital Partners | Henry Ellenbogen | 2.6M | -4,638,500 | $104M | 3.3% | -64% | Existing |
| Maverick Capital | Lee Ainslie | 0 | −796K | — | 0.4% | -100% | EXITED |
| Point72 | Steve Cohen | 0 | −3.3M | — | 0.3% | -100% | EXITED |
Shares Held reflects quarter-end positions for partial reductions. Funds that fully exited show 0 shares held. ∆ Shares is the change from the prior quarter. % of Fund is the prior-quarter position size — how much of the book was sold down.
Signal History
| Quarter | Direction | Funds | Score | vs SPY |
|---|---|---|---|---|
| Q2 2026 | SHORT | 4 | 3.70 | -13.8% |
| Q1 2026 | LONG | 4 | 4.85 | -39.4% |
Same issuer appearing in consecutive quarters — persistent institutional conviction. Returns are frozen at each archived quarter's last refresh.
Insider Activity
| Name | Title | Type | Shares | Price | Value | Filed | Src |
|---|---|---|---|---|---|---|---|
| GIC Private Ltd | — | SELL | 2.1M | $35.05 | $73.22M | 2026-10-06 | ↗ |
| GIC Private Ltd | — | SELL | 7.2M | $35.05 | $251.76M | 2026-10-06 | ↗ |
| GIC Private Ltd | — | SELL | 1.7M | $35.78 | $60.42M | 2026-10-05 | ↗ |
| GIC Private Ltd | — | SELL | 7.1M | $34.33 | $245.35M | 2026-10-02 | ↗ |
| GIC Private Ltd | — | SELL | 2.6M | $35.35 | $90.88M | 2026-10-02 | ↗ |
| GIC Private Ltd | — | SELL | 100K | $35.80 | $3.58M | 2026-08-14 | ↗ |
| GIC Private Ltd | — | SELL | 1.5M | $35.80 | $53.70M | 2026-08-13 | ↗ |
| GIC Private Ltd | — | SELL | 590K | $35.58 | $21.00M | 2026-08-07 | ↗ |
| GIC Private Ltd | — | SELL | 272K | $35.33 | $9.61M | 2026-08-06 | ↗ |
| GIC Private Ltd | — | SELL | 1.7M | $35.46 | $60.67M | 2026-08-05 | ↗ |
| GIC Private Ltd | — | SELL | 266K | $36.48 | $9.69M | 2026-08-05 | ↗ |
Beneficial Ownership (13D/13G)
| Filer | Form | Shares | % of Class | Filed | Src |
|---|---|---|---|---|---|
| Hellman & Friedman Capital Partners X (Parallel), L.P. | SC 13G/A | 61.1M | 6.4% | 2026-08-11 | ↗ |
| BX Mozart ML-2 Holdco L.P. | SC 13G/A | 89.5M | 10.2% | 2026-08-07 | ↗ |
| FMR LLC | SC 13G | 46.9M | 5.5% | 2026-08-06 | ↗ |
| Carlyle Group Inc. | SC 13G/A | 187.1M | 20.6% | 2026-05-15 | ↗ |
| Abu Dhabi Investment Authority | SC 13G/A | 41.4M | 4.9% | 2026-05-07 | ↗ |
| Hellman & Friedman Capital Partners X (Parallel), L.P. | SC 13G/A | 74.5M | 7.9% | 2026-05-06 | ↗ |
| BX Mozart ML-2 Holdco L.P. | SC 13G/A | 109.3M | 12.9% | 2026-05-01 | ↗ |
SC 13D = active intent to influence control (10-day filing deadline after crossing 5%). SC 13G = passive accumulation, no intent to influence control.